Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)56.90
  • Today's Change-0.70 / -1.22%
  • Shares traded65.86m
  • 1 Year change+40.15%
  • Beta1.2108
Data delayed at least 15 minutes, as of Jul 11 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.

  • Revenue in CNY (TTM)29.19bn
  • Net income in CNY6.84bn
  • Incorporated1997
  • Employees20.24k
  • Location
    Jiangsu Hengrui Pharmaceuticals Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
  • Phone+86 2 161053323
  • Fax+86 2 161063801
  • Websitehttps://www.hengrui.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
UCB SA51.55bn8.92bn278.64bn9.38k31.183.2420.155.405.485.4831.6252.770.37411.504.48656,003.406.484.987.976.2071.5271.7117.3113.000.98588.910.231934.2217.144.60210.506.161.842.31
Alnylam Pharmaceuticals, Inc.16.83bn-1.93bn294.37bn2.23k--355.53--17.49-2.09-2.0918.270.88580.58424.129.701,052,959.00-6.71-20.07-8.96-25.5186.0184.18-11.49-55.192.98-0.46270.8988--22.9759.2136.82---24.55--
Daiichi Sankyo Co Ltd91.73bn14.38bn300.12bn19.77k20.903.7516.953.27155.87155.87994.10869.690.54540.87264.2495,434,150.008.555.7210.877.1177.9672.1515.6811.031.85--0.087649.5717.7713.9544.4717.7729.0120.79
Haleon PLC108.71bn13.96bn319.47bn24.00k23.392.06--2.940.15710.15711.221.790.32863.395.49468,041.704.313.675.114.2360.7562.2813.1311.970.77918.480.3843218.65-0.61055.7837.4617.105.53--
Sun Pharmaceutical Industries Ltd43.92bn9.13bn335.08bn43.00k36.705.5529.597.6345.5545.55219.13300.990.59211.074.3312,227,540.0012.369.0915.8312.3879.5673.3820.8816.072.33272.980.031639.348.429.8714.1223.766.6631.95
Takeda Pharmaceutical Co Ltd222.79bn5.25bn338.71bn47.46k65.510.99348.011.5266.8366.832,880.434,407.010.31211.307.2596,545,170.000.73671.710.88152.0465.5167.662.365.990.52022.520.3943123.757.456.84-25.0819.539.821.72
Jiangsu Hengrui Pharmaceuticals Co Ltd29.19bn6.84bn362.97bn20.24k52.697.72--12.431.081.084.617.370.5981.816.051,442,469.0014.0212.6715.3114.0085.5085.6423.4520.069.98--0.002323.8422.633.7447.283.5328.534.60
Merck KGaA178.63bn23.61bn410.98bn62.60k17.391.6410.322.306.486.4849.0868.590.43121.884.89340,745.305.716.047.127.7059.2161.1513.2413.800.831332.430.22529.110.77655.55-1.6616.5416.4211.10
Regeneron Pharmaceuticals Inc100.97bn32.25bn439.41bn15.11k14.452.0912.274.3539.3039.30123.45271.600.39170.63472.61932,457.3012.5118.5213.8921.1386.6987.2231.9437.924.03--0.0843--8.2712.5511.6115.8415.46--
Zoetis Inc66.57bn18.05bn494.55bn13.80k27.8314.8522.867.435.575.5720.5410.440.65291.077.00672,898.6017.7715.2521.8318.3170.9870.1827.2226.321.0421.140.585628.938.338.146.0610.637.3221.37
Data as of Jul 11 2025. Currency figures normalised to Jiangsu Hengrui Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

12.63%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 31 Dec 2024207.13m3.25%
China Asset Management Co., Ltd.as of 30 Apr 2025151.86m2.39%
Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 202491.90m1.44%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 202488.93m1.40%
China Universal Asset Management Co., Ltd.as of 31 Dec 202475.34m1.18%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 202456.12m0.88%
Harvest Fund Management Co., Ltd.as of 31 Dec 202445.25m0.71%
Yinhua Fund Management Co., Ltd.as of 31 Dec 202433.57m0.53%
GF Fund Management Co., Ltd.as of 31 Dec 202429.03m0.46%
Guotai Asset Management Co., Ltd.as of 31 Dec 202425.02m0.39%
More ▼
Data from 31 Dec 2024 - 30 Apr 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.